Articles related to CLINICAL STUDY

Two retina specialists debated whether LIGHTSITE III evidence supports photobiomodulation as treatment for intermediate dry AMD, weighing modest BCVA gains against natural visual acuity variability, study quality concerns, and FDA authorization status.

A phase 3 head-to-head RCT of 689 patients found intravitreal brolucizumab preserved visual acuity at 54 weeks while panretinal photocoagulation patients lost a mean of approximately 4 letters, though intraocular inflammation rates were higher with brolucizumab.

The FDA approved vepdegestrant for ESR1-mutated, ER-positive, HER2-negative advanced breast cancer after endocrine therapy progression, marking the first regulatory approval of a PROTAC drug.

Smartwatch-derived nighttime scratching metrics correlated moderately with disease severity and short-term treatment response in a small pediatric atopic dermatitis cohort.

A post hoc SURPASS-CVOT analysis associated tirzepatide with fewer six-component cardiorenal events than dulaglutide in patients with type 2 diabetes and established ASCVD.

“It’s essentially the same as proving that it’s OK for babies to play with matches, but only if there’s nothing flammable in the area and they’re wearing fireproof clothing.” – William Parker, on over-adjustment in sibling studies